Cargando…

Correction: Clusterin confers gemcitabine resistance in pancreatic cancer

Detalles Bibliográficos
Autores principales:	Chen, Qingfeng, Wang, Zhengkun, Zhang, Kejun, Liu, Xiaoyi, Cao, Weihong, Zhang, Lei, Zhang, Shuhua, Yan, Bomin, Wang, Yaoguang, Xia, Chunping
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3701521/ http://dx.doi.org/10.1186/1477-7819-11-149

Ejemplares similares

Clusterin confers gmcitabine resistance in pancreatic cancer
por: Chen, Qingfeng, et al.
Publicado: (2011)

Correction: Knockdown of clusterin sensitizes pancreatic cancer cells to gemcitabine chemotherapy by ERK1/2 inactivation
por: Tang, Yong, et al.
Publicado: (2013)

Correction: Liang, J., et al. Antisense Oligonucleotide Against Clusterin Regulates Human Hepatocellular Carcinoma Invasion Through Transcriptional Regulation of Matrix Metalloproteinase-2 and E-Cadherin. Int. J. Mol. Sci. 2012, 13, 10594–10607
por: Chen, Dong, et al.
Publicado: (2013)

Antisense Oligonucleotide Against Clusterin Regulates Human Hepatocellular Carcinoma Invasion Through Transcriptional Regulation of Matrix Metalloproteinase-2 and E-Cadherin
por: Chen, Dong, et al.
Publicado: (2012)

Correction: Identification of a novel bile marker clusterin and a public online prediction platform based on deep learning for cholangiocarcinoma
por: Gao, Long, et al.
Publicado: (2023)

Knockdown of clusterin sensitizes pancreatic cancer cells to gemcitabine chemotherapy by ERK1/2 inactivation
por: Tang, Yong, et al.
Publicado: (2012)

Correction to: MiR-10a-5p targets TFAP2C to promote gemcitabine resistance in pancreatic ductal adenocarcinoma
por: Xiong, Guangbing, et al.
Publicado: (2021)

Correction: DUSP1 Is a Novel Target for Enhancing Pancreatic Cancer Cell Sensitivity to Gemcitabine
Publicado: (2014)

Correction: Combination chemotherapy of valproic acid (VPA) and gemcitabine regulates STAT3/Bmi1 pathway to differentially potentiate the motility of pancreatic cancer cells
por: Li, Hehe, et al.
Publicado: (2023)

Clusterin transduces Alzheimer-risk signals to amyloidogenesis
por: Liu, Xi, et al.
Publicado: (2022)

Correction: METTL3 enhances pancreatic ductal adenocarcinoma progression and gemcitabine resistance through modifying DDX23 mRNA N6 adenosine methylation
por: Lin, Chengjie, et al.
Publicado: (2023)

Correction: eIF3f reduces tumor growth by directly interrupting clusterin with anti-apoptotic property in cancer cells
por: Lee, Ji-Yeon, et al.
Publicado: (2017)

Clinical significance of clusterin expression in pancreatic adenocarcinoma
por: Jin, Junshuo, et al.
Publicado: (2012)

Correction: Cancer-associated fibroblasts promote progression and gemcitabine resistance via the SDF-1/SATB-1 pathway in pancreatic cancer
por: Wei, Lusheng, et al.
Publicado: (2021)

Correction: A Ketogenic Diet in Combination with Gemcitabine Increases Survival in Pancreatic Cancer KPC Mice
por: Cortez, Natalia E., et al.
Publicado: (2022)

Correction: The heparan sulfate mimetic PG545 interferes with Wnt/β-catenin signaling and significantly suppresses pancreatic tumorigenesis alone and in combination with gemcitabine
por: Jung, Deok-Beom, et al.
Publicado: (2019)

Correction to: The International Conference on Intelligent Biology and Medicine 2019 (ICIBM 2019): conference summary and innovations in genomics
por: Mathé, Ewy, et al.
Publicado: (2020)

Correction: Inhibition of HIF-1α by PX-478 enhances the anti-tumor effect of gemcitabine by inducing immunogenic cell death in pancreatic ductal adenocarcinoma
por: Zhao, Tiansuo, et al.
Publicado: (2019)

Correction: The anthelmintic drug niclosamide induces GSK-β-mediated β-catenin degradation to potentiate gemcitabine activity, reduce immune evasion ability and suppress pancreatic cancer progression
por: Guo, Yangyang, et al.
Publicado: (2022)

Correction to: The International Conference on Intelligent Biology and Medicine 2019: computational methods for drug interactions
por: Ning, Xia, et al.
Publicado: (2020)

Correction: Bacterial lipopolysaccharide as negative predictor of gemcitabine efficacy in advanced pancreatic cancer – translational results from the AIO-PK0104 Phase 3 study
por: Guenther, Michael, et al.
Publicado: (2021)

Correction to: c-Src confers resistance to mitotic stress through inhibition of DMAP1/Bub3 complex formation in pancreatic cancer
por: Li, Jingjie, et al.
Publicado: (2019)

Correction to: High efficacy of BGD (bendamustine, gemcitabine, and dexamethasone) in relapsed/refractory Hodgkin lymphoma
por: Swoboda, Ryszard, et al.
Publicado: (2021)

Clusterin is a potential molecular predictor for ovarian cancer patient's survival: targeting Clusterin improves response to paclitaxel
por: Hassan, Mohamed K, et al.
Publicado: (2011)

Correction: Musashi2 promotes the development and progression of pancreatic cancer by down-regulating Numb protein
por: Sheng, Weiwei, et al.
Publicado: (2022)

Correction: Digitoflavone Inhibits IκBα Kinase and Enhances Apoptosis Induced by TNFα through Downregulation of Expression of Nuclear Factor κB-Regulated Gene Products in Human Pancreatic Cancer Cells
por: Cai, Xueting, et al.
Publicado: (2013)

Diagnostic value of clusterin immunostaining in hepatocellular carcinoma
por: Li, Yuan, et al.
Publicado: (2020)

Correction to: Exosomes derived from gemcitabine resistant cells transfer malignant phenotypic traits via delivery of miRNA-222-3p
por: Wei, Feng, et al.
Publicado: (2021)

Correction: Non-Secreted Clusterin Isoforms Are Translated in Rare Amounts from Distinct Human mRNA Variants and Do Not Affect Bax-Mediated Apoptosis or the NF-κB Signaling Pathway
por: Prochnow, Hans, et al.
Publicado: (2013)

ROCK2 Confers Acquired Gemcitabine Resistance in Pancreatic Cancer Cells by Upregulating Transcription Factor ZEB1
por: Zhou, Yang, et al.
Publicado: (2019)

Correction to: The prevalence and clinical correlates of medical disorders comorbidities in patients with bipolar disorder
por: Wang, Zhonggang, et al.
Publicado: (2022)

Inhibition of AKT2 Enhances Sensitivity to Gemcitabine via Regulating PUMA and NF-κB Signaling Pathway in Human Pancreatic Ductal Adenocarcinoma
por: Chen, Dong, et al.
Publicado: (2012)

Correction: Innate immune mediator, Interleukin-1 receptor accessory protein (IL1RAP), is expressed and pro-tumorigenic in pancreatic cancer
por: Zhang, Yang, et al.
Publicado: (2022)

Clusterin silencing inhibits proliferation and reduces invasion in human laryngeal squamous carcinoma cells
por: Wang, Qianjin, et al.
Publicado: (2014)

Correction to: ‘Identification of sex chromosome and sex-determining gene of southern catfish based on XX, XY and YY genome sequencing’ (2022) by Zheng et al.
por: Zheng, Shuqing, et al.
Publicado: (2023)

Correction: Thiostrepton induces ferroptosis in pancreatic cancer cells through STAT3/GPX4 signalling
por: Zhang, Weifan, et al.
Publicado: (2022)

Correction: Dissecting cancer heterogeneity based on dimension reduction of transcriptomic profiles using extreme learning machines
por: Wang, Kejun, et al.
Publicado: (2018)

The role of Clusterin in cancer metastasis
por: Peng, Mei, et al.
Publicado: (2019)

Clusterin Expression in Colorectal Carcinomas
por: Téllez, Teresa, et al.
Publicado: (2023)

Clusterin is involved in mediating the metabolic function of adipose SIRT1
por: Zhang, Pengcheng, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_d41uprvghnm5g4rer5oibbhb0s